Knowledge hub

Can AI-based diagnostics support medical institutions during the pandemic? Or is this yet another AI industry hype? Oxipit co-founder and chief operating officer Jogundas Armaitis shares the perspective of the company.

AI medical imaging company has received an Australian Register of Therapeutic Goods Class IIa medical device certificate for ChestEye AI imaging service. Medical device certification paves the way for clinical use of ChestEye in the Australian market. ChestEye imaging suite is already certified by the CE mark. Oxipit received CE certification last February, enabling clinical ChestEye deployment in 32 European countries.

The AI medical imaging company will showcase ChestEye Negative service at Arab Health 2020 conference in Dubai. ChestEye Negative produces preliminary reports for chest X-rays with no abnormality. The service aims to reduce the workload of radiologists, especially in clinical environments, where only a fraction of all studies features an abnormality. It also significantly simplifies large-scale medical screening projects.

EIT Health InnoStars presents a new episode of a series of talks with inspiring people in our community who develop innovative ideas. We ask about their journeys, while developing ideas, their professional career paths and motivations.

Medical imaging technology company Oxipit announced partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria. The partnership aims to introduce vanguard AI diagnostic capabilities and improve detection of 75 pathologies, including tuberculosis, to one of the largest markets in Africa.

The AI medical imaging company will offer a first public preview of Dynamics feature for its award winning ChestEye CAD suite. Dynamics enables a radiologist to compare X-rays and provide automatically generated reports specifically addressing the changes in images over the course of patient treatment. Initially Dynamics feature will support longitudinal comparison for Pneumothorax, Consolidation, Mass, Nodule, Pleural Effusion, Pulmonary Edema and Lung Congestion radiological findings where progress reports are of greatest importance.

A study by the Centre for Advanced Research in Imaging, Neuroscience and Genomics (CARING) found that AI powered CAD software can reduce hedging and defensive reporting statements in radiologist reports, resulting in clearer more actionable diagnosis descriptions. The study was undertaken using Oxipit ChestEye AI imaging suite. Moreover, the study found that nearly 80% of the reports generated by Oxipit ChestEye were as accurate as the radiologists' reports and were more accurate in 5% of analyzed patient cases.

The investment round co-led by Practica Capital, Koinvesticinis fund and angel investors is the largest investment for medical AI solutions in the Baltic states. It is also one of the largest seed rounds among Baltic startups.

Leading AI-based medical imaging solutions provider Oxipit received CE certification for ChestEye radiology imaging suite. Oxipit ChestEye provides analysis and preliminary reports for 75 most common radiological findings - the largest scope of diagnosis currently available on the market - with an average area under curve metric of 93%. CE mark ensures that the software complies with medical device regulations and paves the way for commercial deployments in 32 European countries.

Oxipit, a medical imaging company, has been awarded an “Intelektas. Bendri mokslo-verslo projektai” EU grant for researching and implementing innovative technologies for improved detection of lung nodules as well as diagnosis of pneumothorax and tuberculosis.